Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Watson Gains After Generic Pain Patch Gets U.S. Approval

Watson Pharmaceuticals Inc. rose after the drugmaker’s generic lidocaine patch to treat pain associated with shingles received U.S. regulatory approval.

Watson increased 6 percent to $83.32 at 4 p.m. New York time, its biggest gain in four months.

The patch is a copy of Endo Health Solutions Inc.’s numbing medication Lidoderm, Watson said in a statement yesterday. Watson plans to begin selling the product in September 2013. The Parsippany, New Jersey-based company said it’s eligible to sell the drug for six months without competition.

Watson and Chadds Ford, Pennsylvania-based Endo settled patent litigation related to lidocaine on May 29. Lidoderm is Endo’s best-selling drug, with the company reporting $825 million in sales last year.

Shingles is a painful, blistering skin rash caused by the virus that causes chicken pox, according to the National Institutes of Health.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.